Cocrystal Pharma Inc (NASDAQ:COCP) — Market Cap & Net Worth
Market Cap & Net Worth: Cocrystal Pharma Inc (COCP)
Cocrystal Pharma Inc (NASDAQ:COCP) has a market capitalization of $19.02 Million ($19.02 Million) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #25177 globally and #5102 in its home market, demonstrating a -2.13% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cocrystal Pharma Inc's stock price $1.38 by its total outstanding shares 13785759 (13.79 Million). Analyse cash flow conversion of Cocrystal Pharma Inc to see how efficiently the company converts income to cash.
Cocrystal Pharma Inc Market Cap History: 2015 to 2026
Cocrystal Pharma Inc's market capitalization history from 2015 to 2026. Data shows change from $4.42 Billion to $19.02 Million (-39.61% CAGR).
Index Memberships
Cocrystal Pharma Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.00% | #726 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.00% | #2384 of 3165 |
Weight: Cocrystal Pharma Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cocrystal Pharma Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cocrystal Pharma Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19.81x
Cocrystal Pharma Inc's market cap is 19.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $81.97 Million | $6.56 Million | -$48.17 Million | 12.49x | N/A |
| 2020 | $224.98 Million | $2.01 Million | -$9.65 Million | 111.71x | N/A |
| 2021 | $107.53 Million | $5.43 Million | -$14.19 Million | 19.81x | N/A |
Competitor Companies of COCP by Market Capitalization
Companies near Cocrystal Pharma Inc in the global market cap rankings as of May 4, 2026.
Key companies related to Cocrystal Pharma Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Cocrystal Pharma Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Cocrystal Pharma Inc's market cap moved from $4.42 Billion to $ 19.02 Million, with a yearly change of -39.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $19.02 Million | +40.96% |
| 2025 | $13.50 Million | -51.53% |
| 2024 | $27.85 Million | +17.29% |
| 2023 | $23.74 Million | -11.68% |
| 2022 | $26.88 Million | -75.00% |
| 2021 | $107.53 Million | -52.21% |
| 2020 | $224.98 Million | +174.47% |
| 2019 | $81.97 Million | -86.24% |
| 2018 | $595.54 Million | -40.00% |
| 2017 | $992.57 Million | -48.05% |
| 2016 | $1.91 Billion | -56.74% |
| 2015 | $4.42 Billion | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of Cocrystal Pharma Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $19.02 Million USD |
| MoneyControl | $19.02 Million USD |
| MarketWatch | $19.02 Million USD |
| marketcap.company | $19.02 Million USD |
| Reuters | $19.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C … Read more